---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-340271"
form_type: "8-K"
ticker: "BSEM"
cik: "0001658678"
company_name: "BioStem Technologies, Inc."
filed_at: "2026-08-07T20:15:17+00:00"
generated_at: "2026-08-07T20:16:10.855071+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioStem Technologies approved for Nasdaq Capital Market listing; trading starts Aug 7

## Summary
- Nasdaq approved BSEM common stock for listing on The Nasdaq Capital Market on Aug 6, 2026.
- Trading transitions from OTCQB to Nasdaq effective at market open on Aug 7, 2026; ticker remains BSEM.
- No shareholder action required; CEO Jason Matuszewski cites expanded capital access and liquidity.
- Company is a regenerative medicine firm focused on perinatal tissue allograft products.

## SEC filing metadata
- accession: 0001193125-26-340271
- form_type: 8-K
- ticker: BSEM
- cik: 0001658678
- company_name: BioStem Technologies, Inc.
- filed_at: 2026-08-07T20:15:17+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658678/000119312526340271/0001193125-26-340271-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658678/000119312526340271/bsem-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-340271
- JSON: https://secwatch.observer/filing/0001193125-26-340271.json
- Plain text: https://secwatch.observer/filing/0001193125-26-340271.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.